X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Catalent Completes Acquisition of Cook Pharmica

Yuvraj_pawp by Yuvraj_pawp
24th October 2017
in Americas, Europe, Press Statements

Catalent, Inc , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, announced it has completed the acquisition of Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services.

The acquisition of this Bloomington, Indiana-based biologics contract development and manufacturing organization substantially strengthens Catalent’s position as a leader in biologics development and analytical services, manufacturing and finished product supply. Their complementary capabilities and expertise will help customers accelerate biologic drug development programs and bring better treatments to patients worldwide.

Catalent intends to maximize the benefits of the acquisition through the reorganization of its operations to create two new dedicated business units that will sharpen the focus on growth, performance and customers’ needs.

First, recognizing the company’s substantially increased biopharmaceutical and fill-finish capabilities and the importance of the rapidly growing area of biologics, Catalent has created a business unit focused on Biologics & Specialty Drug Delivery, to be led by Barry Littlejohns as President. He will oversee eight Catalent facilities focused on biologics development, manufacturing, analytical, and sterile fill-finish and Catalent’s respiratory and ophthalmic business platforms. Tedd Green, formerly President of Cook Pharmica, will now serve as Senior Vice President, Catalent Bloomington.

Mr. Littlejohns has been with Catalent for 26 years, initially with its predecessor RP Scherer, and most recently served as President of the company’s former Drug Delivery Solutions business unit.
Second, Catalent has reorganized the remainder of its former Drug Delivery Solutions business into a newly formed Oral Drug Delivery business unit, to be led by Jonathan Arnold as President. Oral Drug Delivery will bring together Catalent’s expertise and capabilities in advanced delivery technologies and development solutions, including formulation and analytical development, bioavailability enhancement including micronization, hot melt extrusion and spray dry technologies, controlled release, Zydis® orally disintegrating tablet technology, and commercial supply across nine facilities.

Mr. Arnold has worked for leading life science organizations for over 23 years. These include RP Scherer, Patheon, and Catalent, where he has held senior business leadership roles in Europe and the U.S. For the past 6-years he has served as Vice President and General Manager for Catalent’s Drug Delivery Solutions business unit.

“The establishment of these focused business units reflects the rapid growth we are seeing across key markets, particularly for biologics and differentiated dosage forms,” commented John Chiminski, Chair and CEO of Catalent. “We have an exciting strategic plan to accelerate our portfolio of capabilities, as evidenced by the recent growth investments we have made, including multi-million-dollar site expansions and the newly completed acquisition of Cook Pharmica. We are confident that the experience and expertise of Barry, Jonathan, and Tedd will provide valuable leadership as we move forward in this exciting phase of our development.”

To arrange a meeting with Mr. Littlejohns or Mr. Arnold at CPhI in Frankfurt, please contact Richard Kerns, Northern Exposure PR at richard@nepr.eu.

Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com

Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu

Investor Contact:
Thomas Castellano
+1 (732) 647 5013
thomas.castellano@catalent.com

ABOUT CATALENT
Catalent, Inc. , is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

 

Tags: Middle East & South Asia
Previous Post

BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn Technology for Parkinson's Disease And ALS

Next Post

Irvine Scientific Will Now Offer Sunlight Medical Pipettes in the United States

Related Posts

Press Statements

Final Report ACHEMA 2022

19th September 2022
Empowering the healthcare fraternity through dynamic online courses
Manufacturing

Empowering the healthcare fraternity through dynamic online courses

9th September 2022
Greene Tweed Highlights Materials for Chemical Processing, Life Sciences, and Hydrogen Power Markets at ACHEMA 2022
Manufacturing

Greene Tweed Highlights Materials for Chemical Processing, Life Sciences, and Hydrogen Power Markets at ACHEMA 2022

27th August 2022
AstraZeneca's Enhertu wins keenly-anticipated U.S. breast cancer nod
FDA Approvals

AstraZeneca’s Enhertu wins keenly-anticipated U.S. breast cancer nod

5th August 2022
Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity
Manufacturing

Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity

2nd August 2022
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
Press Statements

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

1st August 2022
Next Post

Irvine Scientific Will Now Offer Sunlight Medical Pipettes in the United States

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In